J Breast Cancer.  2020 Feb;23(1):100-106. 10.4048/jbc.2020.23.e1.

Acute Lymphoblastic Leukemia in a Patient Treated with Letrozole and Palbociclib

Affiliations
  • 1Division of Hematology-Medical Oncology, Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea. jinhyunpak@gmail.com
  • 2Department of Laboratory Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.
  • 3Department of Pathology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.

Abstract

Palbociclib, in conjunction with endocrine therapy, has been approved for the treatment of patients with advanced breast cancer. The common hematological toxicities associated with palbociclib are leukopenia and neutropenia. However, hematological malignancies have not been reported for palbociclib treatment. Here, for the first time, we present a case of acute lymphoblastic leukemia that was diagnosed in a patient undergoing treatment with letrozole and palbociclib for metastatic breast cancer. This case emphasizes the need for long term follow up of patients treated with palbociclib.

Keyword

Adverse effects; Breast neoplasms; Hematologic neoplasms; Palbociclib; Precursor cell lymphoblastic leukemia-lymphoma

MeSH Terms

Breast Neoplasms
Follow-Up Studies
Hematologic Neoplasms
Humans
Leukopenia
Neutropenia
Precursor Cell Lymphoblastic Leukemia-Lymphoma*
Full Text Links
  • JBC
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error